Table 3

Contralateral lobe –ve (n= 120)

Contralateral lobe +ve (n=65)

P value
(for contralateral disease)

Ipsilateral multifocality -ve (n=90)

Ipsilateral multifocality +ve (n=30)

Ipsilateral multifocality -ve (n=30)

Ipsilateral multifocality +ve (n=35)

Age
   < 40 years (85)
   > 40 years (100) Gender
   Males (47)
   Females (138) Perithyroid extension
   -ve (149)
   +ve (36) LN status
    -ve LN (105)
   +ve LN (80) Pathology
   Papillary carcinoma (152)
   Follicular carcinoma (26)
   Hurthle cell carcinoma (7)

46 (54%)
44 (44%)

26 (55%)
64 (46%)

74 (50%)
16 (44%)

66 (63%)
24 (30%)

69 (45%)
16 (62%)
5 (71%)

13 (15%)
17 (17%)

6 (13%)
24 (18%)

25 (17%)
5 (14%)

8 (8%)
22 (28%)

25(16%)
3(12%)
2 (29%)

12 (14%)
18 (18%)

8 (17%)
22 (16%)

23 (15%)
7 (19%)

14 (13%)
16 (20%)

27(18%)
3 (12%)
0

14 (16%)
21 (21%)

7 (15%)
28 (20%)

27 (18%)
8 (23%)

17 (16%)
18 (22%)

31 (20%)
4 (15%)
0

0.61

0.36

0.29

0.09

0.12

Table 3: Predictive factors of residual malignancy correlated with ipsilateral multifocality in the whole cohort of patients (n= 185).